Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label CLD regimen for previously treated AL amyloidosis
2007-006037-13Phase 2Terminated
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Dec 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, lenalidomide and dexamethasone in light-chain amyloidosis, sponsored by IRCCS San Matteo Foundation. Primary endpoints: Safety and Hematologic and organ response rate. Started Dec 2007; status: terminated.
02
Drugs
cyclophosphamidelenalidomidedexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2007-006037-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006037-13.